Dublin, Jan. 18, 2019 (GLOBE NEWSWIRE) -- The "Peanut Allergy R&D Pipeline Analysis Report, H2-2018" report has been added to ResearchAndMarkets.com's offering. The Peanut Allergy pipeline guide presents complete overview of drugs currently being developed for Peanut Allergy. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Peanut Allergy pipeline candidate. Research and Development progress along with latest news related to each of the Peanut Allergy pipeline candidates is included. Major companies participating in therapeutic development of Peanut Allergy are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided. Amid strong interest for cure of Peanut Allergy from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Peanut Allergy clinical and pre clinical products. The report assists in identifying potential upcoming companies and drugs in Peanut Allergy pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition. Scope of Peanut Allergy pipeline report includes

  • Panorama of Peanut Allergy pipeline markets including statistics on therapeutic drugs and companies involved
  • Peanut Allergy Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Peanut Allergy pipeline candidates across various Mechanism of Actions' are also presented in the study
  • Overview of companies participating in Peanut Allergy pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Peanut Allergy pipeline therapeutics

Key Topics Covered: I. Key Findings 1. Companies Investing in Peanut Allergy Pipeline include Number of Companies with Peanut Allergy projects in pre clinical Development Number of Companies with Peanut Allergy projects in Clinical Development Peanut Allergy Pipeline Companies based in Americas Peanut Allergy Pipeline Companies based in Europe Peanut Allergy Pipeline Companies based in Asia Pacific Peanut Allergy Pipeline Companies based in Rest of the World 2. Pipeline Candidates include Peanut Allergy Pipeline Agents in pre clinical/ Discovery stage of Development Peanut Allergy Pipeline Agents in Clinical Development stage Peanut Allergy Pipeline Therapeutic Compounds received special status Mechanism of Action of most pipeline Drugs Small molecules among the Peanut Allergy Pipeline agents II. Insights into Peanut Allergy Pipeline - 1. Disease Overview Introduction to Peanut Allergy Symptoms and Causes of Peanut Allergy Treatment or Prevention Options for Peanut Allergy Other Details 2. Phase wise Pipeline Compounds Peanut Allergy Pipeline Pre Clinical/ Discovery stage Drugs Peanut Allergy Pipeline Phase 1 stage Drugs Peanut Allergy Pipeline Phase 2 stage Drugs Peanut Allergy Pipeline Phase 3 stage Drugs Peanut Allergy Pipeline Pre Registration stage Drugs 3. Company wise Peanut Allergy Pipeline Compounds 4. Peanut Allergy Pipeline by Mechanism of Action III. Peanut Allergy Pipeline Compound Details Drug Details 1. Snapshot Name of the Therapeutic Agent Originator Developing Company Co Developer/ License Partner Orphan Drug / Fast Track/ Designation Development Phase 2. Drug Overview 3. Mechanism of Action 4. Current Status 5. Clinical Trial Details IV. Peanut Allergy Pipeline Company Briefs V. Latest News and Developments in Global Peanut Allergy Pipeline Market VI. Appendix For more information about this report visit https://www.researchandmarkets.com/research/w...lergy?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Allergy Drugs